Top

Published in:

Open Access 01-12-2017 | Original Article

Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors

Authors: Tsutomu Sugihara, Mitsuru Koizumi, Masamichi Koyama, Takashi Terauchi, Naoya Gomi, Yoshinori Ito, Kiyohiko Hatake, Naohiro Sata

Published in: Annals of Nuclear Medicine | Issue 10/2017

Abstract

Background

This study aimed to compare the detection of bone metastases from breast cancer on F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) and bone scintigraphy (BS). An explorative search for factors influencing the sensitivity or uptake of BS and FDG-PET was also performed.

Methods

Eighty-eight patients with bone metastases from breast cancer were eligible for this study. Histological confirmation of bone metastases was obtained in 31 patients. The bone metastases were visually classified into four types based on their computed tomography (CT) appearance: osteoblastic, osteolytic, mixed, and negative. The sensitivity of BS and FDG-PET were obtained regarding CT type, adjuvant therapy, and the primary tumor characteristics. The FDG maximum standardized uptake value (SUV_max) was analyzed.

Results

The sensitivities of the three modalities (CT, BS, and FDG-PET) were 77, 89, and 94%, respectively. The sensitivity of FDG-PET for the osteoblastic type (69%) was significantly lower than that for the other types (P < 0.001), and the sensitivity of BS for the negative type (70%) was significantly lower than that for the others. Regarding tumor characteristics, the sensitivity of FDG-PET significantly differed between nuclear grade (NG)1 and NG2–3 (P = 0.032). The SUV_max of the osteoblastic type was significantly lower than that of the other types (P = 0.009). The SUV_max of NG1 was also significantly lower than that of NG2–3 (P = 0.011). No significant difference in FDG uptake (SUV_max) was detected between different histological types.

Conclusion

Although FDG-PET is superior to BS for the detection of bone metastases from breast cancer, this technique has limitations in depicting osteoblastic bone metastases and NG1.

Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol. 1983;23:175–80.CrossRefPubMed

Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942–53.CrossRefPubMed

Roberts CC, Daffner RH, Weissman BN, Bancroft L, Bennett DL, Blebea JS, et al. ACR appropriateness criteria on metastatic bone disease. J Am Coll Radiol. 2010;7:400–9.CrossRefPubMed

Tryciecky EW, Gottschalk A, Ludema K. Oncologic imaging: interactions of nuclear medicine with CT and MRI using the bone scan as a model. Semin Nucl Med. 1997;27:142–51.CrossRefPubMed

Arano Y. Recent advances in 99m Tc radiopharmaceuticals. Ann Nucl Med. 2002;16:79–93.CrossRefPubMed

Bender H, Kirst J, Palmedo H, Schomburg A, Wagner U, Ruhlmann J, et al. Value of ¹⁸fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res. 1997;17:1687–92.PubMed

Ohta M, Tokuda Y, Suzuki Y, Kubota M, Makuuchi H, Tajima T, et al. Whole body PET for the evaluation of bony metastases in patients with breast cancer. Comparison with ^99mTc-MDP bone scintigraphy. Nucl Med Commun. 2001;22:875–9.CrossRefPubMed

Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesion. J Clin Oncol. 1998;16:3375–9.CrossRefPubMed

Huyge V, Garcia C, Vanderstappen A, Alexiou J, Gil T, Flamen P. Progressive osteoblastic bone metastases in breast cancer negative on FDG-PET. Clin Nucl Med. 2009;34:417–20.CrossRefPubMed

10.

Uematsu T, Yuen S, Yukisawa S, Aramaki T, Morimoto N, Endo M, et al. Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer. AJR Am J Roentgenol. 2005;184:1266–73.CrossRefPubMed

11.

Shie P, Cardarelli R, Brandon D, Erdman W, Abdulrahim N. Meta-analysis: comparison of F-18 Fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med. 2008;33:97–101.CrossRefPubMed

12.

Rong J, Wang S, Ding Q, Yun M, Zheng Z, Ye S. Comparison of ¹⁸FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis. Surg Oncol. 2013;22:86–91.CrossRefPubMed

13.

Dashevsky BZ, Goldman DA, Parsons M, Gönen M, Corben AD, Jochelson MS, et al. Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype. Eur J Nucl Med Mol Imaging. 2015;42:1666–73.CrossRefPubMedPubMedCentral

14.

Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2005;32:1253–8.CrossRefPubMed

15.

Buck A, Schirrmeister H, Kühn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29:1317–23.CrossRefPubMed

16.

Avril N, Rosé CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000;18:3495–502.CrossRefPubMed

17.

Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F, et al. Glucose metabolism of breast cancer assessed by ¹⁸F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001;42:9–16.PubMed

18.

Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA, Molthoff CF. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379–87.CrossRefPubMed

Title: Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors
Authors: Tsutomu Sugihara
Mitsuru Koizumi
Masamichi Koyama
Takashi Terauchi
Naoya Gomi
Yoshinori Ito
Kiyohiko Hatake
Naohiro Sata
Publication date: 01-12-2017
Publisher: Springer Japan
Published in: Annals of Nuclear Medicine / Issue 10/2017
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-017-1202-3

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors

Abstract

Background

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2017

Inter- and intra-observer reproducibility of quantitative analysis for FP-CIT SPECT in patients with DLB

Assessment of intratumor heterogeneity in mesenchymal uterine tumor by an 18F-FDG PET/CT texture analysis

Textural features and SUV-based variables assessed by dual time point 18F-FDG PET/CT in locally advanced breast cancer

Uptake of AV-1451 in meningiomas

CT-based SPECT attenuation correction and assessment of infarct size: results from a cardiac phantom study

The effect of short-term treatment with lithium carbonate on the outcome of radioiodine therapy in patients with long-lasting Graves’ hyperthyroidism